StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
256940.KQ$6510.00-6.83%
Fair $6510.00+0.0%

256940.KQ

Keeps Biopharma Inc.

Consumer Defensive / Household & Personal ProductsKOSDAQ

$6510.00

-440.00 (-6.83%)

Fairly Valued+0.0%Fair Value $6510.00Fund rank 21/100 · Data gapFallback financials|
SA 19/F
F-Score: 1/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-1.9B · quality 26.3/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -15.8%, below the 5% threshold
Thesis & Journal · 256940.KQLocal privado en este navegador · Keeps Biopharma Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$130.7B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-15.8%

↓

Gross Margin

22.1%

↓

Debt/Equity

1.49

↑
52-Week Range$6510
$5880$22150

TradingView lightweight chart

256940.KQ price, volumen y niveles de valoración

Último $6,000Periodo +70.6%
Fair value: $6,510

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+126.6%

FCF CAGR

—

FCF margin

-29.3%

FCF / Net income

5.09x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $170.15B · net income $-9.79B · FCF $-49.81B

2022-FY → 2025-FY

Gross margin

22.1%+14.9% pts

Operating margin

0.9%+59.9% pts

Net margin

-5.8%+72.1% pts

FCF margin

-29.3%-22.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$170.15B$170.15B$127.58B$92.13B$14.62B
Net Income$-9.79B$-9.79B$1.11B$3.93B$-11.38B
EBITDA$-49.7M$-49.7M$9.68B$8.84B$-11.95B
EPS-499.00-499.0059.00209.00-607.00
Gross Margin22.1%22.1%13.5%13.9%7.1%
Operating Margin0.9%0.9%4.9%3.2%-58.9%
Net Margin-5.8%-5.8%0.9%4.3%-77.8%
Balance Sheet
Debt/Equity1.491.491.110.840.54
Current Ratio4.164.16———
Cash Flow
Free Cash Flow$-49.81B$-49.81B$-1.89B$-1.13B$-996.1M
Returns
ROE-15.8%-15.8%2.2%6.9%-21.4%
Valuation
P/E——94.2429.23—
EV/EBITDA——14.6517.99—
P/B2.062.062.092.012.46
Growth & Yield
Revenue Growth33.4%33.4%38.5%530.3%—
EPS Growth-945.8%-945.8%-71.8%134.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -59.5%

Total return

-59.5%

Start / end P/E

n/dx → n/dx

EPS bridge

59.00 → -499.00

Residual

-59.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-59.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.